Efpeglenatide launch in Korea undercuts Mounjaro and Wegovy on price

Hanmi Pharmaceutical's weekly obesity injection EPPE reached Korean clinics on 29 October 2026, and the efpeglenatide launch arrives with a starting price well under the two market leaders. A local report puts the first four weeks at about 180,000 won, roughly 130 dollars, for patients paying out of pocket. EPPE is the first obesity medicine developed in South Korea and was cleared by the Ministry of Food and Drug Safety on 7 October. Its trial weight loss trails Mounjaro and Wegovy, so the rollout tests whether a lower price and local data can win prescriptions.

What the EPPE price covers in the first month

According to a BigGo Finance report that cites industry figures, Hanmi set a combined supply price of 129,800 won, about 97 dollars, for the first four weeks of treatment. That is the amount charged before a clinic adds its own fees. Patients pay closer to 180,000 won once consultation and other charges are included, and the final bill differs from hospital to hospital. Obesity medicines in South Korea are not covered by national health insurance, so the full amount falls on the patient. The starting month uses the lowest strengths of the injection, and doctors then raise the dose in steps based on how each patient responds. EPPE comes in five strengths, and the supply price rises with each step up.

The report sets this starting cost against the two incumbents. On its figures, the first EPPE month costs about 53 to 70 percent of a comparable Mounjaro start and about 65 to 83 percent of a Wegovy start, with averages near 60 and 75 percent. Those numbers depend on the clinic and cover only the opening weeks, not a full year of therapy, so the outlet's headline claim of a price up to 40 percent lower should be read with care. A fair long term test of the EPPE price would need maintenance costs for all three drugs, and the Mounjaro price at higher strengths is not given. The table below lists the launch facts the report supports.

Efpeglenatide trial data sit below the market leaders

Hanmi's case rests on a Phase 3 trial in 448 Korean adults with obesity, in which participants lost 9.75 percent of body weight on average over 40 weeks, the report says. The company ran the study only in Korean patients and says that a slow dose climb lowered the risk of nausea, vomiting and other stomach side effects. Those are the two arguments it puts beside price: data drawn from the people who will use the drug, and a gentler start. The coverage does not state how the treated group compared with placebo, how many people dropped out, or what share reached common weight loss goals, so the true size of the drug effect is not clear from it.

Hanmi's case rests on a Phase 3 trial in 448 Korean adults with obesity, in which participants lost 9.75 percent of body weight on average over 40 weeks, the report says.

Critics cited in the coverage say this weight loss is smaller than what Mounjaro and Wegovy achieved, and they argue that EPPE needs more proof of efficacy and safety to hold its place. Comparisons across separate trials are rough, because populations, durations and starting weights differ. Still, a gap of this kind matters to doctors choosing a first drug for patients with a lot of weight to lose. Our earlier story on the efpeglenatide approval in Korea framed the same trade: modest efficacy set against tolerability and a domestic evidence base. The efpeglenatide launch does not change those data; it only puts them in front of paying patients for the first time.

Korea obesity drug market braces for a price contest

The Korea obesity drug market has so far been split between Lilly's Mounjaro and Novo Nordisk's Wegovy. The last new entrant already moved prices once. When Mounjaro launched in South Korea in August 2025, Novo Nordisk cut the supply price of Wegovy by as much as 42 percent, according to the report. Some observers now expect the efpeglenatide launch to pull prices lower across the class. That is a forecast, not an event, and neither company has announced a new cut in response to EPPE. Both incumbents sell at very large scale, as our story on Mounjaro sales growth showed, so each can decide whether a smaller rival is worth a price answer.

Insurance could reshape the contest. Novo Nordisk applied in October to the Health Insurance Review and Assessment Service for Wegovy reimbursement, aimed at patients with severe obesity and related conditions. Lilly's Korean unit is reportedly seeking coverage of Mounjaro for adults with type 2 diabetes. If either request succeeds, patients in the covered groups would pay much less, and the cost edge of EPPE would shrink for them. The report does not say whether Hanmi plans to seek coverage for its own drug, and it gives no timeline for either decision. For now, every obesity prescription in Korea is paid in full by the patient, which is the setting where a lower starting price counts most.

Limited supply and a crowded Korean pipeline

Access is the first practical limit. Initial supply is tight, the report says, so EPPE is prescribed at only some hospitals and had not yet reached pharmacies. The coverage gives no supply volumes and no date for wider distribution. A low starting price matters little if patients cannot fill the prescription, and the early weeks of the efpeglenatide launch may say more about manufacturing capacity than about demand. High demand for obesity drugs also draws counterfeit and unregulated injectables into many markets. Legitimate access to EPPE runs through a doctor's prescription at a hospital that has received stock, and any other offer of the drug deserves suspicion.

Hanmi will not have the domestic field to itself for long. JW Pharmaceutical and HK inno.N are preparing or running Phase 3 trials in Korea of candidates licensed from China, Ildong Pharmaceutical is developing an oral drug, and Daewoong Pharmaceutical is working on a monthly injection, according to the report. Daewon's tablet program, covered in our note on DW5324 oral semaglutide exposure, adds another local contender at a much earlier stage. Most of these candidates still have to prove efficacy and safety in large trials. Until they do, EPPE is the only Korean developed obesity drug on the market, and its price sets the bar that newcomers will face.

Conclusion

The efpeglenatide launch moves Hanmi's weekly GLP-1 injection from approval to real prescriptions, with a starting month priced below Mounjaro and Wegovy. It does not change the trial data, which show smaller weight loss than the leaders, and supply is still limited. The next signals are whether the incumbents cut prices, how Korea's insurer rules on Wegovy and Mounjaro coverage, and whether Hanmi publishes fuller Phase 3 results. This story is research reporting, not medical advice.